Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)

US · MD National Institutes of Health (NIH) grant open #PAR-25-040

Response due Sep 07, 2026 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting research applications under a Funding Opportunity Announcement (FOA) focused on schizophrenia and related disorders as they manifest during mid- to late-life. The R21 mechanism supports exploratory/developmental research projects. Clinical trials are optional under this announcement. The opportunity is open from November 2024 through September 2026, allowing multiple submission cycles.

What they want

Funding exploratory and developmental research (R21 mechanism) on schizophrenia and related psychotic disorders as they occur in mid- to late-life populations. Clinical trials are permitted but not required. Applicants must address research gaps related to the onset, progression, treatment, or biological underpinnings of schizophrenia-spectrum conditions in aging individuals.

How they evaluate

Submission: Grants.gov federal grants portal (PAR-25-040)

Risks & flags

Narrow, highly specific scientific focus (schizophrenia/related disorders in mid-to-late life) may limit applicant pool to a small number of specialized research groups
No dollar value or award ceiling disclosed in the provided text, limiting cost competitiveness assessment

Market context

inferred from NAICS

R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)

NAICS 541715

US market size: $95B
Typical award: $100K – $50M+

Typical buyers

DoDNSFNIHNASADOE

Commonly required

DCAA-compliant accountingITARCMMC L2

Schizophrenia and related disorders during…

Due Sep 07

Onboard ↗